Illumina Inc., which makes instruments for genetic analysis, said Friday that two shareholder advisory firms are recommending that Illumina shareholders reject Roche Holding AG's offer to buy the company.
Illumina Inc., which makes instruments for genetic analysis, said Friday that two shareholder advisory firms are recommending that Illumina shareholders reject Roche Holding AG’s offer to buy the company.
Institutional Shareholder Services Inc. said the Swiss drugmaker’s offer of $51 per share, or about $6.5 billion, is inadequate, and it is advising Illumina shareholders to vote reject the bid.
Illumina said Egan-Jones Ratings Co. also recommends that shareholders reject Roche Holding AG’s proposals and support the board candidates Illumina has nominated instead of Roche’s choices.
In January, Roche went public with an offer to buy Illumina for $5.7 billion, or $44.50 per share. Illumina said that price was too low, and Roche responded in late March with a bigger offer.
- UW tops new list of best western universities
- Microsoft co-founder says he found sunken Japan WWII warship
- Moneytree leads push to loosen state's payday-lending law
- Should UW stick with coach Lorenzo Romar?
- Seattle's micro-housing boom offers an affordable alternative
Most Read Stories
Illumina said the new offer remains insufficient, and it accused Roche of trying to take advantage of a decline in the company’s share price in late 2010.
Roche said Friday that it is disappointed with the ISS recommendation, and said its offer is a sufficient basis for talks between the companies. It said it would be willing to raise its bid again if Illumina will start talks.
After Roche took its offer public, Illumina adopted a “poison pill” shareholder rights measure intended to ward off unwanted attempts to acquire the company. Roche has nominated a slate of directors to Illumina’s board as part of its effort to gain control of the company.
Shares of Illumina closed at $52.33 on Thursday, and U.S. stock markets were closed Friday.